CME Information

2006 Conference on Innovations and Challenges in Prostate Cancer

Earn up to 2.0 Complimentary CME AMA PRA Category 1 Credits™

TARGET AUDIENCE

Urologists, medical and radiation oncologists, and othermedical professionals involved in the assessment and treat-ment of prostate cancer patients.

HOW TO OBTAIN CREDIT

● Review the learning objectives below and read the activity(Summary Statement) in its entirety before completing theself-assessment test and registration.● On-line: for “real-time” credit, go to www.informedicalcme.com/cme.html and complete activity on-line.● Fax/Mail: complete post-test, evaluation and registrationand fax/mail registration/evaluation as directed on form.● A certificate will be mailed within 30 days.● Release date: September 2007. Expiration date: September2008.

LEARNING OBJECTIVE

Following successful completion of this CME activity, par-ticipants should be able to: discuss current recommenda-tions for assessing and treating prostate cancer patientswith low risk disease, intermediate/high risk disease, risingprostate specific antigen after local therapy and castrationresistant disease.

EDUCATIONAL NEED

This educational journal supplement and the summarystatement comprising the CME activity have been designedto address the need to: summarize and communicate currentrecommendations from academic leaders in the field onavailable and near-term management strategies and thera-pies for low risk, intermediate/high risk and refractory pros-tate cancer; reinforce the importance of multidisciplinaryconsultation to optimize patient outcomes; and highlightinformation on clinical trials of new therapies that may be ofbenefit to their patients.

CME SPONSORSHIP

This enduring CME activity has been planned and imple-mented in accordance with the Essential Areas and Policiesof the Accreditation Council for Continuing Medical Educa-tion (ACCME) by InforMEDical Communications, Inc. Infor-MEDical is accredited by the ACCME to provide continuing

medical education for physicians and takes responsibility for

0022-5347/07/1783-0002/0THE JOURNAL OF UROLOGY®

Copyright © 2007 by AMERICAN UROLOGICAL ASSOCIATION

S2

the content, quality and scientific integrity of this CMEactivity.

CREDIT DESIGNATION

InforMEDical designates this educational activity for a max-imum of 2.0 AMA PRA Category 1 Credits™. Each physicianshould claim credit commensurate with the extent of his/herparticipation in the activity.

FINANCIAL DISCLOSURE

The program faculty has reported the following financialrelationships with commercial pharmaceutical, deviceand/or biotechnology companies: T. M. Beer: Novacea: con-sultant, investor, shareowner. P. R. Carroll: DOD: investi-gator; NCI: investigator; TAP: investigator. A. D’Amico:Nothing to disclose. R. S. DiPaola: Nothing to disclose.M. A. Eisenberger: Celgene: grant; Cell Genesys: consul-tant; Centocor: grant; GenVec: data safety monitoring com-mittee; Merck: advisory board; Oncogenix: data safety moni-toring committee; sanofi-aventis: advisory board, consultant,grants. M. Hussain: Abbott: research grant; AstraZeneca:stockholder; Bristol-Myers Squibb: advisory board/consul-tant, research grant; Centocor: advisory board/consultant;Chiron: advisory board/consultant; Elan: advisory board/con-sultant; GlaxoSmithKline: stockholder; Johnson & Johnson:stockholder; Lilly: advisory board/consultant; Merck: researchgrant, stockholder; Novacea: advisory board/consultant;Pfizer: advisory board/consultant; sanofi-aventis: researchgrants; Wilex: research grant. P. W. Kantoff: Nothing todisclose. W. K. Kelly: Bristol-Myers Squibb: consultant, re-search support; CuraGen: research support; Novartis: con-sultant; sanofi-aventis: consultant, research support. P.Mathew: Nothing to disclose. M. J. Morris: Agensys: re-search funding; Cytogen: research funding; sanofi-aventis:consultant. C. J. Ryan: Nothing to disclose. Howard M.Sandler: TAP: consulting. I. M. Thompson: Nothing todisclose.

EDUCATIONAL GRANT SUPPORT

This enduring CME activity is based on a symposium heldOctober 30–31, 2006 in Cambridge, Massachusetts. The pro-gram was supported by educational grants provided by Ab-bott Laboratories, sanofi-aventis U.S., AstraZeneca Phar-maceuticals, Novartis Pharmaceuticals and Dendreon.

TEST KEY

1 d; 2 b; 3 e; 4 d; 5 a; 6 c; 7 e; 8 d

Vol. 178, S2, September 2007Printed in U.S.A.

DOI:10.1016/j.juro.2007.06.003